newsfilter
← Latest News
Earnings Call Transcripts·

Jefferies Global Healthcare Conference in London - ALX ONCOLOGY HOLDINGS INC

  • Explicit Guidance:

    • ALX-2004 Data Update: Expect to report on 35–40 total patients, with 15 or more at efficacious doses in head and neck, lung, and esophageal cancer, by next month (December KOL event).
    • ALX-2004 Enrollment: Target completion of 120 patients in the ongoing Phase 2 study during the second half of the year.
    • Pivotal Trial Readiness: Aiming to have sufficient data by the end of 2027 to initiate a registration (Phase 3) study or an End-of-Phase 2 meeting.
    • Cash Position: Raised $150 million in January to fund execution through upcoming milestones; no new guidance issued.
  • Business-Segment Outlook:

    • ALX-2004 (EGFR-Targeted ADC): Focusing enrollment primarily on head and neck and lung (high EGFR expressors) due to superior commercial opportunity, with a "smattering" of esophageal and CRC patients.
    • ALX-2004 Clinical Trajectory: Plan to move from current 4th-line monotherapy trials into 2nd-line monotherapy, with potential combination strategies (e.g., Pembrolizumab) for 1st-line advancement pending data.
    • ALX-419 (CD47/Bivalent): No immediate data updates expected, but program is considered to have reached an "inflection point" as a targeted IO play with 800+ patients dosed, allowing for optimized study design based on biomarker understanding.
    • ESMO/HER2 Setting: High unmet need identified in HER2+ patients progressing on standard care; enrollment enthusiasm "better than expected."
  • Market and Competitive Outlook:

    • Differentiation Strategy: ALX-2004 utilizes Metuzumab (binding a non-Cetuximab epitope), offering distinct advantage over competitors (e.g., Amgen's Amivantamab, Pendo's data) that use Cetuximab; this enables potential use in post-Cetuximab progression patients and unique combination strategies.
    • Competitive Landscape (Head & Neck): Anticipates competition from bispecifics (e.g., Pendo in frontline, Amgen in 2nd line); ALX-2004 aims to be the "first topo ADC" in the class.
    • Competitive Landscape (Lung): Focus on wild-type squamous lung where competitors (e.g., Daiichi Sankyo, Seagen) face limitations; high EGFR expression in squamous tumors viewed as a specific opportunity.
    • Efficacy Benchmarks: Targets ORR >20% in 4th-line setting to be considered "outstanding" and >30% as "transformational" (approaching 2nd-line benchmarks); expects standard of care in 4th-line to be ~5% to high single-digit percent ORR.
    • Safety Benchmarks: Targeting rash incidence of ≤30% (vs. 70–90% for Cetuximab/panitumumab), specifically aiming to minimize Grade 3+ events and keep GI toxicities manageable.
  • Macro / Industry Outlook:

    • Tumor Biology: Confidence that EGFR expression levels may not be strictly requisite for efficacy if the correct epitope is targeted, though current trials focus on high-expressing tumors.
    • Regulatory Pathways: Single-arm accelerated approval considered possible for 2nd-line indications (citing Amgen's precedent); randomized trials expected if advancing to 1st-line or specific lung indications (TBD).
  • Strategic Initiatives:

    • Combination Therapies: Exploring unique combinations with other EGFR agents (e.g., Amivantamab, Pendo) due to distinct epitope binding, enabling dual-epitope targeting similar to HER2 in breast cancer.
    • Payload Strategy: Leveraging Topoisomerase I (Topo-1) payload for potency while managing toxicity, contrasting with MMAE-based competitors.
    • M&A/Capital: Financially well-funded via recent Blackstone and OrbiMed participation; capacity exists to execute all milestone plans without immediate capital constraints.
  • Risks and Headwinds to Outlook:

    • Data Dependency: Regulatory path (single-arm vs. randomized) and line-of-therapy advancement are explicitly "data dependent."
    • Toxicity Realization: Risk that GI toxicities (nausea, vomiting, diarrhea, myelosuppression) or rash may not meet target safety profiles, potentially limiting tolerability or duration of treatment.
    • Enrollment Variability: While enthusiasm is high, the timeline for generating 30%+ ORR data remains early-stage; no guarantee of signal strength in the 15-patient cohort.
    • Competitive Pressure: Potential for other ADCs and bispecifics to define standard of care in earlier lines, forcing accelerated development timelines.
  • Management Tone on the Future:

    • Confidence: High confidence in the "bifurcated eat/don't eat" CD47 approach and the unique Metuzumab epitope strategy for ALX-2004; describes current program as "very much now a targeted IO play."
    • Aggressiveness: Willing to target high-risk 4th-line populations to demonstrate potency; seeks to move to 2nd and 1st lines rapidly pending positive signals.
    • Transparency: Commitment to detailed data sharing (swimmer plots, waterfall plots, spider plots) regarding efficacy and dose levels in the upcoming update.
    • Hedges: Frequent use of "we think," "we hope," and "data dependent" regarding efficacy targets and regulatory pathways.
  • Miscellaneous:

    • Timeline: Next data update for ALX-2004 occurs next month (December KOL event); more Phase 2 patients expected in H2; Phase 3/Registration readiness targeted by end of 2027.
    • Study Design: Current ALX-2004 trial is U.S.-only across major academic centers (e.g., Moffitt, MD Anderson).
Company
ALX ONCOLOGY HOLDINGS INC
Keywords
ALX ONCOLOGY HOLDINGS INC